← All trials
NCT04904549
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 26, 2021
- Primary completion
- Mar 8, 2023
- Completion date
- Mar 8, 2023
- First posted
- May 27, 2021
- Last posted
- Nov 29, 2021
- Enrollment
- 21046
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Sanofi-AventisLead sponsor
- SanofiStudy director
- GlaxoSmithKlineCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.